Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorJinling Hospital, China
About this trial
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Newly diagnosed renal cell carcinoma
Without any treatment
Agree and accept radical surgical treatment
Signed written informed consent
Disqualifiers
Had other cancers
Had received any antitumor therapy before
Known or suspected active autoimmune disease
Informed consent is not possible due to medical or psychiatric problems
Trial population
RCC patients undergoing surgical treatment
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
To explore the predictive effect of ctDNA methylomics on the prognosis and medication guidance of renal carcinoma.
Time frame
5 years2
To explore the advance time of ctDNA methylomics in monitoring postoperative recurrence of renal cancer compared with imaging.
Time frame
5 years3
The molecular mechanism of renal cancer recurrence was analyzed with baseline tissue and circulating methylation profiles.
Time frame
5 years4
A renal cancer recurrence risk model was established based on clinical information, molecular risk factors and ctDNA methylomics
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov